CDKN2A and glioblastoma: This deletion leads to the loss of p16 (INK4a), which regulates Rb signaling; p14 (ARF), which modulates the p53 tumor suppressor pathway; and p15 (INK4b), which inhibits CDK4 activity, collectively promoting GBM proliferation and resistance to cell cycle control mechanisms [80].